Millikan K W, Gleason T G, Deziel D J, Doolas A
Department of General Surgery, Rush Medical College, Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois.
Ann Surg. 1993 Nov;218(5):621-9. doi: 10.1097/00000658-199321850-00006.
The recent experience with U tubes at Rush-Presbyterian-St. Lukes Medical Center was reviewed in order to assess their current role in hepatobiliary surgery.
Transhepatic intubation by a variety of methods has been used routinely for biliary decompression and inhibition of anastomotic stricture since the 1960s. U tubes were popularized in the early 1970s. However, little has been written about their use and efficacy in recent years. Because of the apparent benefits associated with the use of U tubes versus other stenting techniques, the authors performed this study.
The hospital and office charts of all patients who had U tubes placed between 1980 and 1992 were reviewed retrospectively. Between 1980 and 1992, U tubes were placed intraoperatively in 54 patients for biliary decompression and/or stenting. Twelve patients were operated on for benign causes of obstruction. Forty-two patients with malignant tumors underwent surgery for U tube placement in conjunction with or without tumor resection and anastomotic bypass.
There was a 0% operative mortality rate in the benign group. In six patients, the U tube played a major role in the long-term management of their disease processes. None of these patients has had restricture since removal of the tube. In the malignant group, the 30-day operative mortality rate was 12%. After 3 months, marked clinical improvement and complete biliary decompression were achieved, with mean bilirubin levels dropping from 14.0 mg/dL to 1.3 mg/dL. No patients in the malignant group required reoperation for recurrent biliary obstruction after U tube placement.
The use of U tubes is advocated for biliary decompression and/or anastomotic stenting in patients with benign stricture or resectable malignancy and in patients with nonresectable, malignant biliary obstruction for adequate palliation of intractable jaundice.
回顾拉什长老会圣卢克医疗中心使用U形管的近期经验,以评估其目前在肝胆外科手术中的作用。
自20世纪60年代以来,通过各种方法进行的经肝插管已常规用于胆道减压和抑制吻合口狭窄。U形管在20世纪70年代初得到推广。然而,近年来关于其使用和疗效的报道很少。由于与使用U形管相比其他支架技术具有明显优势,作者进行了这项研究。
对1980年至1992年间所有放置U形管患者的医院病历和门诊病历进行回顾性分析。1980年至1992年间,54例患者术中放置U形管用于胆道减压和/或支架置入。12例患者因良性梗阻原因接受手术。42例恶性肿瘤患者接受了U形管置入手术,同时或不同时进行肿瘤切除和吻合口旁路手术。
良性组手术死亡率为0%。6例患者中,U形管在其疾病过程的长期管理中发挥了主要作用。这些患者在拔除U形管后均未出现狭窄。恶性组30天手术死亡率为12%。3个月后,临床症状明显改善,胆道完全减压,平均胆红素水平从14.0mg/dL降至1.3mg/dL。恶性组患者在放置U形管后均无需因复发性胆道梗阻再次手术。
对于良性狭窄或可切除恶性肿瘤患者以及不可切除的恶性胆道梗阻患者,为充分缓解顽固性黄疸,提倡使用U形管进行胆道减压和/或吻合口支架置入。